New guidance for gene therapy developers, Lilly’s deal for kidney drugs, and more biotech news from The Readout
Adobe
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Yesterday was a brutal day for biotech stocks, but one company withstood the broad selloff. We also look at investor excitement for longevity startups and yet another licensing deal made by Eli Lilly.
